Skip to Main Content

Lawrence D. Kaplan


Director, Lymphoma Program

Dr. Lawrence D. Kaplan, a hematologist-oncologist, directs UCSF's lymphoma program. He is an international leader in the treatment of lymphoma and HIV-associated lymphoma.

In his research, Kaplan is particularly interested in developing new treatments for lymphoma and the HIV-related form of this cancer.

Kaplan earned his medical degree at the David Geffen School of Medicine at UCLA. He completed a residency in medicine at Boston Medical Center and completed a fellowship in hematology and oncology at UCSF. He joined UCSF in 1985.

Kaplan's professional activities include serving on the Lymphoma Working Group of the AIDS Malignancy Consortium, a clinical trials group supported by the National Cancer Institute (NCI). He formerly chaired the group's steering committee. He also serves on the lymphoma committee of Alliance for Clinical Trials in Oncology, a national research group sponsored by the NCI.

  • Education

    UCLA, 1980

  • Residencies

    Boston Medical Center, Medicine, 1983

  • Fellowships

    UCSF, Hematology and Oncology, 1985

  • Board Certifications

    Medical Oncology, American Board of Internal Medicine

    Internal Medicine, American Board of Internal Medicine

  • Academic Title


  • Languages


Where I see patients (1)

    My reviews


    Overall Experience
    224 Ratings
    Explained things in a way that was easy to understand
    222 Ratings
    Did the doctor pay attention to your concerns
    223 Ratings
    Gave easy to understand instructions about taking care of health problems or concerns
    220 Ratings
    Knew the important information about your medical history
    223 Ratings
    The provider showed respect for what you had to say
    223 Ratings
    The provider spent enough time with me
    223 Ratings
    Decorative Caduceus

    Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disea...

    The Kaplan-Meier method will be used to estimate OS, including medians and confidence intervals. Comparison of OS between treatment arms will be conducted using a one-sided log-rank test stratified with mantle cell lymphoma Intern...


    Decorative Caduceus

    Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving ...

    Timely engraftment is defined as a persistent an absolute neutrophil count (ANC) of at least 500 cells/mm3 and a platelet count of at least 20,000 cells/mm3 for at least 3 days


    Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF are covered by every insurance plan.